Physician profile
Michael A Webber
NPI 1114197613
$9,316.12
in general payments reported to CMS, 2019-2025
34 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $998 · 2021: $1,252 · 2022: $1,199 · 2023: $1,532 · 2024: $1,168 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,271 · Education: $60.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,270.87 |
| Education | $60.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,823.32 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $653.87 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $642.13 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $589.75 | 2021-2024 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $566.47 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $563.58 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $476.58 | 2019-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $444.70 | 2019-2024 | Jornay Pm |
| Allergan, INC. | $428.49 | 2019-2020 | |
| Axsome Therapeutics, INC. | $412.74 | 2022-2025 | Auvelity, Sunosi |
| Corium, LLC | $353.97 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $311.18 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $276.90 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $253.34 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Lundbeck LLC | $183.96 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $140.37 | 2020-2025 | Adzenys Xr-Odt |
| Arbor Pharmaceuticals, INC. | $139.98 | 2020 | |
| Bausch Health US, LLC | $133.74 | 2019-2025 | Aplenzin, Wellbutrin |
| Jazz Pharmaceuticals INC. | $122.97 | 2019-2021 | |
| Adlon Therapeutics L.P. | $121.18 | 2019-2021 | |
| Checkpoint Surgical, INC | $117.08 | 2022 | |
| Noven Therapeutics, LLC | $116.83 | 2024-2025 | Xelstrym, Secuado |
| Zimmer Biomet Holdings, INC. | $103.92 | 2019 | |
| Vertical Pharmaceuticals, LLC | $94.37 | 2019-2025 | Relexxii |
| Alkermes, INC. | $77.41 | 2019-2022 | |
| Shire North American Group INC | $39.58 | 2019 | |
| Avanir Pharmaceuticals, INC. | $31.55 | 2019-2020 | |
| Almatica Pharma LLC | $19.55 | 2023 | Loreev Xr |
| Harmony Biosciences LLC | $16.35 | 2025 | |
| Alfasigma USA, INC. | $12.50 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.47 | 2022 | |
| Sage Therapeutics, LLC | $12.42 | 2019 | |
| Tris Pharma INC | $11.69 | 2020 | |
| Indivior INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Webber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.